Canada markets closed
  • S&P/TSX

    20,157.65
    +19.30 (+0.10%)
     
  • S&P 500

    4,255.15
    +7.71 (+0.18%)
     
  • DOW

    34,393.75
    -85.85 (-0.25%)
     
  • CAD/USD

    0.8233
    +0.0005 (+0.06%)
     
  • CRUDE OIL

    71.13
    +0.22 (+0.31%)
     
  • BTC-CAD

    48,349.34
    +722.27 (+1.52%)
     
  • CMC Crypto 200

    995.01
    +26.17 (+2.70%)
     
  • GOLD FUTURES

    1,867.20
    -12.40 (-0.66%)
     
  • RUSSELL 2000

    2,326.15
    -9.66 (-0.41%)
     
  • 10-Yr Bond

    1.5010
    +0.0390 (+2.67%)
     
  • NASDAQ

    14,174.14
    +104.72 (+0.74%)
     
  • VOLATILITY

    16.39
    +0.74 (+4.73%)
     
  • FTSE

    7,146.68
    +12.62 (+0.18%)
     
  • NIKKEI 225

    29,161.80
    +213.07 (+0.74%)
     
  • CAD/EUR

    0.6791
    -0.0001 (-0.01%)
     

Freeline to Participate at the 2021 RBC Capital Markets Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

LONDON, May 12, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that senior management will participate in a Fireside Chat at the virtual 2021 RBC Capital Markets Global Healthcare Conference on Tuesday, May 18, 2021 at 4:50 pm EDT.

A webcast of the event will be available on the Investors section of the Freeline website. Senior management will also participate in virtual one-on-one meetings with investors at the conference.

About Freeline Therapeutics

Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (“AAV”) vector-mediated systemic gene therapies. The Company is dedicated to improving patient lives through innovative, one-time treatments that provide functional cures for inherited systemic debilitating diseases. Freeline uses its proprietary, rationally-designed AAV vector, along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing protein into the patient’s bloodstream. The Company’s integrated gene therapy platform includes in-house capabilities in research, clinical development, manufacturing and commercialization. The Company has clinical programs in Hemophilia B and Fabry disease, as well as preclinical programs in Gaucher disease and Hemophilia A. Freeline is headquartered in the UK and has operations in Germany and the US.

Contact

David S. Arrington
Vice President Investor Relations & Corporate Communications
Freeline Therapeutics
david.arrington@freeline.life
+1 (646) 668 6947